Eric Shifrut

The paper uses CRISPR to assess the functional impact of IL2RG variants in human T cells, confirming known annotations and identifying novel loss-of-function mutations.

The paper identifies that TNFα secretion by tumor-infiltrating myeloid DCs is critical for CD8 T cell cytotoxicity, and shows that DC vaccines lose this function, limiting their efficacy.

This study shows that sustained exposure of human HSPCs to CAR-T cell secretome impairs their function, but this effect is reversible with dual TNFα-IFNγ blockade.

This paper performs in vivo CRISPR screens in human T cells to identify genetic modifiers of T cell function in solid tumors, finding P2RY8-G13 and GNAS as key regulators.

The paper constructs a single-cell splicing atlas of human CD8 T cells and identifies isoform-specific immune checkpoints that enhance effector function and tumor control.

The paper introduces memento, a method for differential expression analysis of scRNA-seq data, and shows it identifies significant differences in mean, variability, and gene correlation across experimental conditions.

This paper describes a method to efficiently generate genetically modified primary human myeloid cells using CRISPR-Cas9 RNP nucleofection, demonstrating its utility in studying HIV-1 infection and myeloid cell biology.

The paper uses CRISPR perturbations and single-cell transcriptomics to identify gene regulators and interactions in CD4+ T cells, revealing 134 regulators and 194 regulator pairs.

This paper introduces ITCell, a method that predicts CD4 T-cell epitopes by integrating antigen cleavage, MHCII presentation, and TCR recognition, achieving higher accuracy than single-stage methods.

This paper develops a non-viral CRISPR-Cas9 system for precise genome editing in human T cells, enabling therapeutic reprogramming of cell function and specificity.

This study tracks changes in CD4 T cell receptor repertoires after immunization using short CDR3 sequences, showing distinct repertoires at different time points post-vaccination.